AdaptHealth (AHCO) to Release Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect AdaptHealth to post earnings of $0.06 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a negative net margin of 21.21% and a positive return on equity of 8.84%. The firm had revenue of $858.23 million during the quarter, compared to analysts’ expectations of $825.94 million. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Price Performance

AdaptHealth stock opened at $10.26 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.21 and a debt-to-equity ratio of 1.44. AdaptHealth has a 52-week low of $6.37 and a 52-week high of $15.37. The firm has a market cap of $1.36 billion, a PE ratio of -1.93, a price-to-earnings-growth ratio of 0.68 and a beta of 1.06. The company’s 50 day moving average is $10.32 and its two-hundred day moving average is $8.52.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Jefferies Financial Group cut AdaptHealth from a “buy” rating to a “hold” rating and reduced their price objective for the company from $14.50 to $8.00 in a research note on Monday, January 8th. UBS Group boosted their price objective on AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Truist Financial raised their target price on shares of AdaptHealth from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.10.

Insider Buying and Selling

In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now owns 11,643,769 shares of the company’s stock, valued at $128,314,334.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder James E. Flynn sold 52,487 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $10.93, for a total transaction of $573,682.91. Following the transaction, the insider now owns 11,826,376 shares in the company, valued at approximately $129,262,289.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the sale, the insider now owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The disclosure for this sale can be found here. 13.60% of the stock is owned by company insiders.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.